The 2016 Banff liver allograft rejection global assessment provides a framework for determining the severity of liver transplant rejection based on inflammatory patterns observed in liver tissue samples. This system categorizes the rejection into four distinct outcomes based on specific criteria associated with the nature and extent of the inflammatory infiltrate.

To apply this assessment:

- If the inflammation is identified as a portal and/or perivenular infiltrate related to an immune reaction without adequate tissue damage to qualify for more severe categories, the result is "Indeterminate."
- For rejection-related infiltrates present in only a few triads or perivenular areas, characterized by mild and mostly portal-confined inflammation without necrosis for isolated perivenular infiltrates, the diagnosis is "Mild rejection."
- When the infiltrate expands through most or all of the portal tracts or perivenular areas, sometimes accompanied by necrosis or hepatocyte dropout in some perivenular regions, it is classified as "Moderate rejection."
- Finally, if there is substantial spillover into periportal areas or significant perivenular inflammation that extends into the hepatic parenchyma, coupled with widespread perivenular hepatocyte necrosis, the assessment indicates "Severe rejection."

This structured approach ensures a consistent evaluation by focusing on the specific features and distribution of inflammatory infiltrate and related tissue damage.

The calculator in question is the "2016 Banff Liver Allograft Rejection Global Assessment". This scoring system is used specifically in the patient population of individuals who have undergone liver transplantation. The clinical utility of this calculator is to assess the severity of liver allograft rejection, which is a common complication post-transplantation. It helps clinicians to determine the appropriate treatment strategy and to predict the prognosis of the patient. The scoring system takes into account various histological features of the liver biopsy, including portal inflammation, bile duct inflammation and damage, venous endothelial inflammation, and hepatocyte changes. There are no specific exclusion criteria for its use, but it should be noted that this scoring system is based on histological findings, so it is not applicable in cases where a liver biopsy is not performed or not feasible.